Cited 9 times in
Clinical and biochemical characteristics of nonobese type 2 diabetic patients with glutamic acid decarboxylase antibody in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강은석 | - |
dc.contributor.author | 김경래 | - |
dc.contributor.author | 안철우 | - |
dc.contributor.author | 이현철 | - |
dc.contributor.author | 임승길 | - |
dc.contributor.author | 차봉수 | - |
dc.date.accessioned | 2015-06-10T11:56:10Z | - |
dc.date.available | 2015-06-10T11:56:10Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 0026-0495 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/108889 | - |
dc.description.abstract | We evaluated the prevalence of glutamic acid decarboxylase autoantibody (GADA) in nonobese patients with type 2 diabetes mellitus in Korea and investigated the characteristics of GADA-positive and GADA-negative patients. Two years later, we assessed the progression of beta-cell function in these patients. Of the 647 nonobese patients with type 2 diabetes mellitus enrolled in the study, 10.1% was positive for GADA. Glutamic acid decarboxylase antibody–positive patients had lower fasting and stimulated C-peptide levels compared with GADA-negative patients (1.70 ± 0.72 vs 1.24 ± 0.59 μg/L, P < .001; 2.59 ± 1.51 vs 1.99 ± 0.82 μg/L, P < .001). Patients treated with insulin had lower fasting and stimulated C-peptide levels than those not treated (1.13 ± 0.52 vs 1.66 ± 0.73 μg/L, P = .002; 1.85 ± 0.69 vs 2.49 ± 0.91 μg/L, P = .004) and had higher titers of GADA (30.5 ± 7.3 vs 6.0 ± 4.8 U/mL, P < .001). In terms of progression of beta-cell function, fasting and stimulated C-peptide levels were significantly lower in GADA-positive patients after 2 years (from 1.24 ± 0.59 to 0.95 ± 0.54 μg/L, P = .004; from 1.99 ± 0.82 to 1.61 ± 0.77 μg/L, P = .007), whereas no such difference was observed in the GADA-negative patients. We demonstrate that a significant proportion of Korean patients may be positive for GADA; this is consistent with studies of white subjects, although disagrees with previous reports on Korean subjects. By assessing the presence of GADA in Korean type 2 diabetic patients, we are able to predict their course of beta-cell function and identify in advance those who are likely to require insulin treatment. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1107~1112 | - |
dc.relation.isPartOf | METABOLISM-CLINICAL AND EXPERIMENTAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Age of Onset | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Anthropometry | - |
dc.subject.MESH | Autoantibodies/analysis* | - |
dc.subject.MESH | Body Mass Index | - |
dc.subject.MESH | C-Peptide/metabolism | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/enzymology | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/epidemiology | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/immunology* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Glutamate Decarboxylase/immunology* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypoglycemic Agents/therapeutic use | - |
dc.subject.MESH | Insulin/therapeutic use | - |
dc.subject.MESH | Korea/epidemiology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.title | Clinical and biochemical characteristics of nonobese type 2 diabetic patients with glutamic acid decarboxylase antibody in Korea | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Chul Sik Kim | - |
dc.contributor.googleauthor | Jae Hyun Nam | - |
dc.contributor.googleauthor | Ji Sun Nam | - |
dc.contributor.googleauthor | Jong Suk Park | - |
dc.contributor.googleauthor | Eun Seok Kang | - |
dc.contributor.googleauthor | Chul Woo Ahn | - |
dc.contributor.googleauthor | Bong Soo Cha | - |
dc.contributor.googleauthor | Sung Kil Lim | - |
dc.contributor.googleauthor | Kyung Rae Kim | - |
dc.contributor.googleauthor | Hyun Chul Lee | - |
dc.contributor.googleauthor | Kap Bum Huh | - |
dc.identifier.doi | 10.1016/j.metabol.2006.04.006 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00068 | - |
dc.contributor.localId | A00294 | - |
dc.contributor.localId | A02270 | - |
dc.contributor.localId | A03301 | - |
dc.contributor.localId | A03375 | - |
dc.contributor.localId | A03996 | - |
dc.relation.journalcode | J02223 | - |
dc.identifier.eissn | 1532-8600 | - |
dc.identifier.pmid | 16839848 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0026049506001405 | - |
dc.contributor.alternativeName | Kang, Eun Seok | - |
dc.contributor.alternativeName | Kim, Kyung Rae | - |
dc.contributor.alternativeName | Ahn, Chul Woo | - |
dc.contributor.alternativeName | Lee, Hyun Chul | - |
dc.contributor.alternativeName | Lim, Sung Kil | - |
dc.contributor.alternativeName | Cha, Bong Soo | - |
dc.contributor.affiliatedAuthor | Kang, Eun Seok | - |
dc.contributor.affiliatedAuthor | Kim, Kyung Rae | - |
dc.contributor.affiliatedAuthor | Ahn, Chul Woo | - |
dc.contributor.affiliatedAuthor | Lee, Hyun Chul | - |
dc.contributor.affiliatedAuthor | Lim, Sung Kil | - |
dc.contributor.affiliatedAuthor | Cha, Bong Soo | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 55 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1107 | - |
dc.citation.endPage | 1112 | - |
dc.identifier.bibliographicCitation | METABOLISM-CLINICAL AND EXPERIMENTAL, Vol.55(8) : 1107-1112, 2006 | - |
dc.identifier.rimsid | 49945 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.